A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03740529 |
Recruitment Status :
Active, not recruiting
First Posted : November 14, 2018
Last Update Posted : March 26, 2024
|
Sponsor:
Loxo Oncology, Inc.
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Eli Lilly and Company ( Loxo Oncology, Inc. )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | September 2027 |
Estimated Study Completion Date : | January 2028 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):